Literature DB >> 17240244

Is Her-2/neu expressed in nonepithelial ovarian malignancies?

Joseph Menczer1, Letizia Schreiber, Bernard Czernobilsky, Esther Berger, Abraham Golan, Tally Levy.   

Abstract

OBJECTIVE: The objective of this study was to assess the expression of Her-2/neu in nonepithelial ovarian malignancies. STUDY
DESIGN: Formalin-fixed paraffin-embedded archival tissue blocks of 20 unselected nonepithelial ovarian malignancies (12 granulosa cell tumors and 8 germ cell tumors) diagnosed between 1993 and 2005 were immunohistochemically stained for Her-2/neu.
RESULTS: Immunohistochemical staining for Her-2/neu was not present in any of these nonepithelial malignancies examined.
CONCLUSION: Our limited sample size does not allow a generalized conclusion concerning the lack of Her-2/neu expression in nonepithelial ovarian malignancies, but it adds information with regard to the expression of this oncogene in these rare neoplasms and seems to indicate that it is not a frequent occurrence.

Entities:  

Mesh:

Year:  2007        PMID: 17240244     DOI: 10.1016/j.ajog.2006.07.050

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

1.  Granulosa Cell Tumors: Novel Predictors of Recurrence in Early-stage Patients.

Authors:  Sharif Sakr; Eman Abdulfatah; Sumi Thomas; Zaid Al-Wahab; Rafic Beydoun; Robert Morris; Rouba Ali-Fehmi; Sudeshna Bandyopadhyay
Journal:  Int J Gynecol Pathol       Date:  2017-05       Impact factor: 2.762

2.  Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors.

Authors:  C Papila; H Uzun; H Balci; H Zerdali; C Sezgin; Günay Can; H Yanardag
Journal:  Med Oncol       Date:  2008-10-15       Impact factor: 3.064

3.  HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study.

Authors:  Anniina Färkkilä; Noora Andersson; Ralf Bützow; Arto Leminen; Markku Heikinheimo; Mikko Anttonen; Leila Unkila-Kallio
Journal:  Cancer Med       Date:  2014-03-29       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.